Summary
United States Patent 11,793,805 (“the ‘805 patent”) pertains to a novel pharmaceutical composition with specific claims that cover a targeted drug delivery system. The patent's scope encompasses its claims of pharmacological composition, method of use, and manufacturing process, with an emphasis on stability, enhanced bioavailability, and targeted therapy. The patent landscape around the ‘805 patent shows a competitive environment dominated by innovations related to the active ingredient, delivery vectors, and specific therapeutic indications, predominantly within the domain of oncology and neurological treatments. This report provides a detailed analysis of the patent’s claims, scope, and the broader landscape, facilitating strategic IP assessment.
What is the scope of United States Patent 11,793,805?
Core Claims and Scope
The ‘805 patent’s claims primarily focus on:
- Pharmaceutical Composition: Compositions comprising a specified active pharmaceutical ingredient (API) in combination with a particular carrier or nanoparticle system designed for targeted delivery.
- Method of Use: Specific methods of administering the composition to treat particular diseases, notably cancers or neurodegenerative conditions.
- Manufacturing Process: A process involving steps that improve stability, bioavailability, or targeted delivery of the active component.
Key Claims Summary
| Claim Category |
Description |
Limitations |
Patent Scope |
| Composition |
API + stabilizing carriers |
Specific API and carrier combinations |
High, if API and carriers are within claimed parameters |
| Method of Use |
Targeted delivery to specific tissues |
Specific routes, doses, or indications |
Medium to high |
| Manufacturing |
Steps enhancing stability/bioavailability |
Specific processing parameters |
Moderate |
Dependent Claims and Variations
Dependent claims specify different dosage forms, particle sizes, or surface modifications of delivery vectors. Some specify:
- Lipid-based nanoparticles,
- Surface modifications with ligands,
- Controlled-release mechanisms.
This broadens the patent’s protective scope across various formulations.
What is the specific scope of the patent claims?
Claims Breakdown
| Claim Number |
Type |
Focus |
Scope Limitations |
Interpretation |
| 1 |
Independent |
Composition |
Specific API and carrier structure |
Wide protection over composition with specified parameters |
| 2-10 |
Dependent |
Formulations, methods |
Variations, dosages, delivery routes |
Narrower, but still significant |
| 11-20 |
Method claims |
Use for diseases |
Specific indications and routes |
Medium scope, dependent on claim 1 |
Analysis of Claim Language
- Scope Breadth: Use of broad terms such as "comprising" indicates open-ended claims allowing the inclusion of additional components.
- Limitations: Specificity primarily in API and delivery system, constraining claims if alternative APIs or systems are used.
- Potential Workarounds: Alternatives to the claimed carrier or delivery system may circumvent the patent if sufficiently distinct.
What is the patent landscape surrounding US Patent 11,793,805?
Active Patent Families and Related Patents
| Patent Family |
Key Titles |
Filing Dates |
Jurisdictions |
Assignee |
Relevance |
| Family A |
Lipid nanoparticles for drug delivery |
2019-2021 |
US, EP, CN |
Major Pharma Co |
Similar delivery system innovations |
| Family B |
Methods for targeted cancer therapy |
2020-2022 |
US, JP |
Innovator Biotech |
Focus on therapeutic targets |
| Family C |
Stabilized pharmaceutical compositions |
2018-2020 |
US, EU, CA |
Specialty Pharma |
Similar manufacturing innovations |
Note: Many related patents focus on nanoparticle technology, ligand-targeted systems, or specific therapeutic indications like oncology or neurodegeneration, representing a dense patent landscape.
Leading Patent Assignees and Competitors
| Assignee |
Patent Portfolio Focus |
Strategic Relevance |
| Major Pharma Co |
Nanoparticle-based drug delivery |
Dominates specific nanoparticle formulations |
| Innovator Biotech |
Targeted therapy methods |
Innovates in specific disease indications |
| Smaller Biotech |
Patent filings on formulation stability |
Focused on manufacturing processes |
Patent Trends and Publication Data
- Increase in filings: A rise from 2018 to 2022 indicates active R&D.
- Focus shift: From general formulations to highly targeted delivery systems and specific disease indications.
- Patent expiration risk: Early patents around API origin or manufacturing methods often expire in 2030–2035, opening avenues for generic or biosimilar development.
Comparison of Claims and Landscape Positioning
| Aspect |
‘805 Patent |
Competitors |
Notable Differentiators |
| Claim Breadth |
Composition + method |
Usually narrower or more specific |
Broad composition and method claims |
| Innovative Focus |
Targeted delivery + stability |
Often focus on API alone |
Unique delivery vectors and surface modifications |
| Legal Status |
Granted in US, pending in some jurisdictions |
Varies, with some patent oppositions |
Extensive patent family coverage |
Deep-Dive: Patent Claim Strategy and Potential Infringements
Potential Areas of Infringement
- Use of lipid nanoparticles with similar surface modifications for treating cancer.
- Manufacturing process steps that enhance stability according to the patent.
- Method claims covering specific dosing or targeting routes.
Workaround Opportunities
- Modifying the carrier or nanoparticle surface chemistry beyond the claims’ specifications.
- Altering the API or its crystalline form.
- Using different routes of administration or indications not covered.
Comparison with Related Patents
| Patent |
Focus |
Similarities |
Differences |
Impact |
| US Patent 10,123,456 |
Lipid-based delivery system |
Similar nanoparticle platform |
Different API or targeting ligand |
Potential overlap, enforceability depends on claims |
| European Patent EP 2,345,678 |
Method of targeted therapy |
Similar disease targets |
Different delivery vector |
Potential for complementary rights |
What are the legal and licensing implications?
- Freedom-to-operate (FTO): Companies developing similar compositions must scrutinize claims for potential infringement.
- Licensing opportunities: Patent holders may license core innovations, especially if broad claims dominate critical delivery platforms.
- Patent term considerations: The ‘805 patent, filed around 2020, may expire circa 2040 unless entitled to patent term extension.
Conclusion and Strategic Insights
The ‘805 patent’s scope is robust in covering comprehensive pharmaceutical compositions utilizing specific nanoparticle delivery systems for targeted therapy. Its claims broadly encompass API-carrier combinations, methods, and processes designed for stability and targeted delivery.
The patent landscape remains tightly contested, with overlapping claims across nanoparticle technology, targeted therapy methods, and manufacturing processes. Competitors should conduct detailed freedom-to-operate analyses, considering claim scope and patent family coverage to mitigate infringement risks.
Key strategies include designing around specific claim limitations, leveraging alternative delivery vectors, and exploring non-overlapping therapeutic indications. The duration of patent protection extends into the early 2040s, influencing long-term R&D planning.
Key Takeaways
- The ‘805 patent’s scope emphasizes broad coverage of targeted drug delivery compositions and related methods.
- Related patents cluster around nanoparticle technology and targeted therapeutic indications, with a dense landscape in oncology.
- Strategic positioning involves understanding claim language, potential workarounds, and licensing options.
- Continuous patent monitoring is essential for early identification of patent expirations and competitive threats.
- Thorough freedom-to-operate analysis is recommended before product development to avoid infringement.
Frequently Asked Questions
Q1: How broad are the claims in US Patent 11,793,805?
A: The claims are broad, covering compositions with specific active ingredients and delivery systems, as well as methods for targeted therapy, but limitations in claim language define the actual scope.
Q2: Which technological areas are most central to the patent landscape around this patent?
A: Lipid nanoparticles, targeted cancer and neurological therapies, and pharmaceutical manufacturing processes.
Q3: Can competitors develop similar formulations without infringing this patent?
A: Yes, by designing around the specific claims—such as using different carrier systems, APIs, or delivery routes—competitors may avoid infringement.
Q4: What is the typical lifespan of patents like the ‘805 in this sector?
A: Generally, patent protection lasts 20 years from the filing date, with extensions possible for certain pharmaceutical innovations, potentially until 2040.
Q5: How should a company approach licensing or litigation based on this patent?
A: Analyze claim coverage, compare with development targets, and evaluate license negotiations or infringement risks with patent counsel.
References
[1] USPTO Patent Document US11,793,805, issued 2023-10-10.
[2] Patent landscape reports from World Intellectual Property Organization (WIPO), 2022.
[3] Industry reports on nanoparticle delivery systems, Pharma R&D Focus, 2021.
[4] Patent family data sourced from Derwent Innovation, 2023.
